I'm LongbridgeAI, I can summarize articles.Positive phase III melanoma data validates the T-cell priming approach, with broad ongoing trials in lung, bladder, and renal cancers. Manufacturing is already at commercial scale, supporting global trials and future launches. The expanding vaccine portfolio and innovative mRNA technology underpin growth and margin confidence.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.